Pionyr And Abcam Extend Partnership To Evaluate TREM2-Expressing Cells In Cancer Patients

 Pionyr Immunotherapeutics, Inc., a University of California, San Francisco founded company developing first-in-class antibody therapeutics that increase the body’s anti-tumor immunity and Abcam a global innovator in life science reagents and tools, announced the extension of their collaboration with a new commercial licensing agreement to support the progression of PY314, the first to the clinic of Pionyr’s compounds.